Bloomage Biotechnology Corp Ltd Net Assets
Bloomage Biotechnology Corp Ltd net assets. Based on the latest financial reports, Bloomage Biotechnology Corp Ltd (688363) has net assets worth CN¥7.16 Billion CNY (≈ $1.05 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.75 Billion ≈ $1.28 Billion USD) and total liabilities (CN¥1.59 Billion ≈ $232.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Bloomage Biotechnology Corp Ltd (688363) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.16 Billion |
| % of Total Assets | 81.82% |
| Annual Growth Rate | 25.36% |
| 5-Year Change | 24.77% |
| 10-Year Change | 464.4% |
| Growth Volatility | 42.78 |
Net Assets of Bloomage Biotechnology Corp Ltd (2012–2025)
Net assets of Bloomage Biotechnology Corp Ltd from 2012 to 2025. This chart illustrates how Bloomage Biotechnology Corp Ltd's net assets have evolved over time, based on quarterly financial data. See Bloomage Biotechnology Corp Ltd (688363) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Bloomage Biotechnology Corp Ltd (2012–2025)
The table below shows the annual net assets of Bloomage Biotechnology Corp Ltd from 2012 to 2025. For live market cap and overall valuation, see 688363 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.12 Billion ≈ $1.04 Billion |
+4.03% |
| 2024-12-31 | CN¥6.84 Billion ≈ $1.00 Billion |
-2.06% |
| 2023-12-31 | CN¥6.98 Billion ≈ $1.02 Billion |
+4.50% |
| 2022-12-31 | CN¥6.68 Billion ≈ $977.93 Million |
+17.19% |
| 2021-12-31 | CN¥5.70 Billion ≈ $834.45 Million |
+11.94% |
| 2020-12-31 | CN¥5.09 Billion ≈ $745.44 Million |
+11.97% |
| 2019-12-31 | CN¥4.55 Billion ≈ $665.74 Million |
+164.90% |
| 2018-12-31 | CN¥1.72 Billion ≈ $251.32 Million |
+4.87% |
| 2017-12-31 | CN¥1.64 Billion ≈ $239.65 Million |
+29.91% |
| 2016-12-31 | CN¥1.26 Billion ≈ $184.47 Million |
+5.76% |
| 2015-12-31 | CN¥1.19 Billion ≈ $174.42 Million |
+58.40% |
| 2014-12-31 | CN¥752.51 Million ≈ $110.12 Million |
+33.34% |
| 2013-12-31 | CN¥564.35 Million ≈ $82.58 Million |
+49.71% |
| 2012-12-31 | CN¥376.97 Million ≈ $55.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bloomage Biotechnology Corp Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 889.1% over the analyzed period, indicating profitable operations and earnings retention.
Bloomage Biotechnology Corp Ltd Net Assets Breakdown (December 2025)
Bloomage Biotechnology Corp Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.69 Billion | 37.90% |
| Other Components | CN¥4.40 Billion | 62.10% |
| Total Equity | CN¥7.09 Billion | 100.00% |
Bloomage Biotechnology Corp Ltd Competitors by Market Cap
The table below lists competitors of Bloomage Biotechnology Corp Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Boise Cascad Llc
NYSE:BCC
|
$2.45 Billion |
|
Procter & Gamble Hygiene and Health Care Limited
NSE:PGHH
|
$2.45 Billion |
|
Redefine Properties Ltd
JSE:RDF
|
$2.45 Billion |
|
Bank of Xi'An Co Ltd
SHG:600928
|
$2.45 Billion |
|
First Merchants Corporation
NASDAQ:FRME
|
$2.45 Billion |
|
Mivne Real Estate KD Ltd
TA:MVNE
|
$2.45 Billion |
|
BREVILLE GROUP LTD
F:HDE
|
$2.45 Billion |
|
Companhia de Gás de São Paulo - COMGÁS
SA:CGAS3
|
$2.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bloomage Biotechnology Corp Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,810,170,453 to 7,085,653,979, a change of 275,483,526 (4.0%).
- Net income of 292,058,566 contributed positively to equity growth.
- Dividend payments of 56,078,755 reduced retained earnings.
- Other comprehensive income decreased equity by 412,625,510.
- Other factors increased equity by 452,129,225.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥292.06 Million | +4.12% |
| Dividends Paid | CN¥56.08 Million | -0.79% |
| Other Comprehensive Income | CN¥-412.63 Million | -5.82% |
| Other Changes | CN¥452.13 Million | +6.38% |
| Total Change | CN¥- | 4.05% |
Book Value vs Market Value Analysis
This analysis compares Bloomage Biotechnology Corp Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 28.94x to 2.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.20 | CN¥34.76 | x |
| 2013-12-31 | CN¥1.68 | CN¥34.76 | x |
| 2014-12-31 | CN¥2.20 | CN¥34.76 | x |
| 2015-12-31 | CN¥3.46 | CN¥34.76 | x |
| 2016-12-31 | CN¥3.43 | CN¥34.76 | x |
| 2017-12-31 | CN¥4.45 | CN¥34.76 | x |
| 2018-12-31 | CN¥3.93 | CN¥34.76 | x |
| 2019-12-31 | CN¥9.48 | CN¥34.76 | x |
| 2020-12-31 | CN¥10.46 | CN¥34.76 | x |
| 2021-12-31 | CN¥11.80 | CN¥34.76 | x |
| 2022-12-31 | CN¥13.79 | CN¥34.76 | x |
| 2023-12-31 | CN¥14.41 | CN¥34.76 | x |
| 2024-12-31 | CN¥14.07 | CN¥34.76 | x |
| 2025-12-31 | CN¥14.71 | CN¥34.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bloomage Biotechnology Corp Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.96%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.23x
- Recent ROE (4.12%) is below the historical average (14.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 23.69% | 32.47% | 0.58x | 1.26x | CN¥51.58 Million |
| 2013 | 16.73% | 25.16% | 0.49x | 1.36x | CN¥37.97 Million |
| 2014 | 21.54% | 33.67% | 0.50x | 1.28x | CN¥86.82 Million |
| 2015 | 15.97% | 29.25% | 0.30x | 1.85x | CN¥71.20 Million |
| 2016 | 21.37% | 36.75% | 0.44x | 1.34x | CN¥143.36 Million |
| 2017 | 13.57% | 27.17% | 0.43x | 1.15x | CN¥58.50 Million |
| 2018 | 24.68% | 33.56% | 0.61x | 1.21x | CN¥252.14 Million |
| 2019 | 12.87% | 31.06% | 0.38x | 1.09x | CN¥130.57 Million |
| 2020 | 12.87% | 24.53% | 0.46x | 1.14x | CN¥143.86 Million |
| 2021 | 13.73% | 15.81% | 0.66x | 1.32x | CN¥212.43 Million |
| 2022 | 14.64% | 15.27% | 0.73x | 1.31x | CN¥307.54 Million |
| 2023 | 8.53% | 9.75% | 0.72x | 1.22x | CN¥-101.85 Million |
| 2024 | 2.56% | 3.24% | 0.62x | 1.27x | CN¥-506.75 Million |
| 2025 | 4.12% | 6.96% | 0.48x | 1.23x | CN¥-416.51 Million |
Industry Comparison
This section compares Bloomage Biotechnology Corp Ltd's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $1,482,230,453
- Average return on equity (ROE) among peers: 13.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bloomage Biotechnology Corp Ltd (688363) | CN¥7.16 Billion | 23.69% | 0.22x | $2.45 Billion |
| Chongqing Sanxia Paints Co Ltd (000565) | $221.32 Million | 10.55% | 0.74x | $361.65 Million |
| Hengyi Petrochemical Co Ltd (000703) | $224.74 Million | 11.11% | 0.05x | $7.45 Billion |
| Guangdong Xinhui Meida Nylon Co Ltd (000782) | $928.69 Million | 2.92% | 0.77x | $710.31 Million |
| Luxi Chemical Group Co Ltd (000830) | $8.64 Billion | 2.92% | 1.90x | $3.06 Billion |
| China Minmetals Rare Earth Co Ltd (000831) | $1.09 Billion | 2.57% | 1.98x | $7.39 Billion |
| Anhui Guofeng Plastic Industry Co Ltd (000859) | $1.06 Billion | 0.44% | 0.74x | $1.01 Billion |
| Cofco Biochemical Anhui Co Ltd (000930) | $1.96 Billion | 47.38% | 2.04x | $1.30 Billion |
| Shandong Link Science and Technology Co Ltd (001207) | $147.73 Million | 27.85% | 0.93x | $758.53 Million |
| Zhejiang Transfar Co Ltd (002010) | $379.82 Million | 13.84% | 0.21x | $1.85 Billion |
| Poly Union Chemical Holding Group Co Ltd (002037) | $164.57 Million | 18.57% | 1.02x | $465.20 Million |
About Bloomage Biotechnology Corp Ltd
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers beauty and care products under brand Hymagic-VCHA VC Hylauronic Acid; Biomeet-MarineDNA; Bioyouth-SPG Schizophyllan Gel; Hymagic-GluHA; Bloomsurfact EncapCare RP; Bloomsurfact Sodium Surfactin; Hybloom Minitrue; Bioyouth-EGT Pure Ultrapure Ergothioneine; miniHA HA-Oligo degraded by… Read more